Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Sheeba Irshad, Sultan Abdul-Jawad et al.|The Lancet Oncology|2021Cited by 614
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesLeticia Monin, Sheeba Irshad, Adam G. Laing et al.|medRxiv|2021Cited by 61
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer CentreBeth Russell, Saoirse Dolly, Charlotte Moss et al.|Cancers|2022Cited by 4
1608P The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer CentreSaoirse Dolly, M. Van Hemelrijick, Beth Russell et al.|Annals of Oncology|2021Cited by 0
1868P Real-world safety of the 6-weekly pembrolizumab regimen in cancer patients treated in South East LondonMatthaios Kapiris, A. L. Georgiou, L. Cain et al.|Annals of Oncology|2021Cited by 0